Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Introduction Liver cancer has a global incidence of approximately 850,000 cases and represents the fourth leading cause of cancer-related mortality (1).”
BackgroundMEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets
Kumar, S., Stecher, G., & Tamura, K. (2016) · Molecular Biology and Evolution · doi:10.1093/molbev/msw054 · Cited by 44,059 · cited 2×
“Using somatic coding (missense, nonsense, and canonical splice site) variations only, we performed phylogenetic tree estimation, using the maximum parsimony method with default settings in MEGA7 (39).”
MethodInfluentialThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“From CCLE, we obtained the data for all of the available CCA and HCC cell lines (n = 20) that were tested using drugs in our screen (11 drugs) (26).”
MethodIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 2×
“While understudied in human CCA, genetic intratumor heterogeneity has been recognized in other human cancers, such as renal cell carcinoma and HCC (7, 8, 10).”
BackgroundZhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“excellent for high-throughput drug screening (24).”
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406 · cited 2×
“Hepatocellular carcinoma (HCC) accounts for 80%–85% of all cases of primary liver cancer, while cholangiocarcinoma (CCA) accounts for most of the remaining of cases (2, 3).”
BackgroundYang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051 · cited 1×
“Similarly, from GDSC, we obtained available data for CCA and HCC cell lines (n = 16) that were tested with drugs in our data set (29 unique drugs) (27).”
MethodDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“Drug repurposing strategies are well known in diverse areas of medicine, including oncology (32, 33).”
BackgroundPrinciples of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859 · cited 1×
“Initial drug testing experiments were performed on one CCA PDO line, with a 9-drug panel, at a typical high-throughput drug screening concentration of 10 μM (23).”
MethodLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531 · cited 2×
“While multiple somatic alterations were identified in HCC, the vast majority of molecular/targeted agents tested to date have shown minimal if any significant clinical benefit (4).”
BackgroundProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619 · cited 2×
“PDOs were established according to published protocols (18).”
MethodOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 5×
“For example, we found that dasatinib, recently reported as effective in a liver cancer organoid study (17), was effective (survival of less than 15%) in only 3 out of 27 PDO lines.”
BackgroundInfluentialCytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases
Chu, P., Wu, E., & Weiss, L. M. (2000) · Modern Pathology · doi:10.1038/modpathol.3880175 · Cited by 1,024
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684 · cited 1×
“In addition, HDAC inhibitors also appear to be pan-effective, which is mechanistically plausible given that chromatin-modifying genes were found in one of our earlier studies as top mutated genes in CCA (38).”
BackgroundSelf-citationAdvances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · cited 3×
“Patient-derived xenograft (PDX) models can also be utilized for cancer drug screening, either to characterize activity of new lead compounds, or in a personalized fashion to identify best chemotherapy for a specific patient (11).”
BackgroundInfluentialHepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
Singal, A. G., & El-Serag, H. B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.014 · Cited by 530 · cited 2×
“Hepatocellular carcinoma (HCC) accounts for 80%–85% of all cases of primary liver cancer, while cholangiocarcinoma (CCA) accounts for most of the remaining of cases (2, 3).”
BackgroundLeung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., & Tiedemann, R. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.009 · Cited by 383 · cited 1×
“However, in terms of predicting response to the pan-effective drugs discovered here, no known genetic alteration (mutational or otherwise) predicts the response of human cancers to proteasome inhibitors (35, 36).”
BackgroundBonora, M., Wieckowski, M. R., Chinopoulos, C., Kepp, O., Kroemer, G., Galluzzi, L., & Pinton, P. (2015) · Oncogene · doi:10.1038/onc.2014.96 · Cited by 330
Intratumor Heterogeneity in Hepatocellular Carcinoma
Friemel, J., Rechsteiner, M., Frick, L., Böhm, F., Struckmann, K., Egger, M., Moch, H., Heikenwalder, M., & Weber, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0122 · Cited by 296 · cited 2×
“While understudied in human CCA, genetic intratumor heterogeneity has been recognized in other human cancers, such as renal cell carcinoma and HCC (7, 8, 10).”
BackgroundDrug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294 · cited 2×
“Repurposing is attractive because of the anticipated reduction in costs and acceleration of development timelines (31).”
BackgroundResultRepurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.008 · Cited by 242
Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., Qi, L., Zhang, T., Li, Q., Zhang, Z., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.033 · Cited by 214 · cited 1×
“While understudied in human CCA, genetic intratumor heterogeneity has been recognized in other human cancers, such as renal cell carcinoma and HCC (7, 8, 10).”
Background(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.442 · Cited by 173
Bonora, M., Wieckowsk, M. R., Chinopoulos, C., Kepp, O., Kroemer, G., Galluzzi, L., & Pinton, P. (2015) · Oncogene · doi:10.1038/onc.2014.462 · Cited by 163
Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.121 · Cited by 163
Jain, R., Fischer, S. E., Serra, S., & Chetty, R. (2009) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181ad36ea · Cited by 153 · cited 2×
“(E and F) Primary human cancer tissue and a matched PDO established from the same tissue slice was used for hematoxylin and eosin staining as well as for immunohistochemistry (CK7 is a bile duct marker, and mucicarmine is a mucin marker).”
BackgroundGao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X., Worthley, D. L., Wang, X.-Y., Niu, G., Xia, Y., Deng, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.008 · Cited by 132
NCI-60 Cell Line Screening: A Radical Departure in its Time
Chabner, B. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv388 · Cited by 92 · cited 3×
“After 1985, the growing realization that human solid cancers are molecularly heterogeneous led to the development and utilization of 60 human cell lines for drug testing in oncology (the NCI-60) (30).”
BackgroundInfluentialSasaki, M., Sato, Y., & Nakanuma, Y. (2016) · Histopathology · doi:10.1111/his.13084 · Cited by 70
Mitra, A., Harding, T., Mukherjee, U. K., Jang, J. S., Li, Y., Res, H., Jen, J., Sonneveld, P., Kumar, S. K., Kuehl, W. M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.56 · Cited by 50
Cavalloni, G., Neia, C. P., Sassi, F. P., Chiorino, G., Sarotto, I., Aglietta, M., & Leone, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2136-1 · Cited by 42 · cited 1×
“Unfortunately, liver cancers tend to display relatively low engraftment rates, rendering liver cancer PDX models impractical for functional diagnostics (12).”
BackgroundWhy Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
Orlowski, R. Z. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.014 · Cited by 33 · cited 1×
“However, in terms of predicting response to the pan-effective drugs discovered here, no known genetic alteration (mutational or otherwise) predicts the response of human cancers to proteasome inhibitors (35, 36).”
Background
Cited by
Establishment of patient-derived cancer organoids for drug-screening applications
Driehuis, E., Kretzschmar, K., & Clevers, H. (2020) · Nature Protocols · doi:10.1038/s41596-020-0379-4 · Cited by 654
Human organoids in basic research and clinical applications
Tang, X.-Y., Wu, S., Wang, D., Chu, C., Hong, Y., Tao, M., Hu, H., Xu, M., Guo, X., & Liu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01024-9 · Cited by 484
Systems Biology of Cancer Metastasis
Suhail, Y., Cain, M. P., Vanaja, K., Kurywchak, P. A., Levchenko, A., Kalluri, R., & Kshitiz (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.003 · Cited by 452
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Xenograft and organoid model systems in cancer research
Bleijs, M., van de Wetering, M., Clevers, H., & Drost, J. (2019) · The EMBO Journal · doi:10.15252/embj.2019101654 · Cited by 400
Metadata
- Authors
- Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., Ewald, A. J., Mezey, E., Bader, J. S., & Selaru, F. M.
- Venue
- JCI Insight
- Published
- 2019-01-24
- Volume
- 4
- Issue
- 2
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2912813083
- Cited by
- 215
- References
- 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.